Recently, bevacizumab (Avastin) has gained popularity as a potential treatment of choroidal neovascular-ization, macular edema, and proliferative retinopa-thies. Bevacizumab is a 149-kd full-length humanized anti-vascular endothelial growth factor A murine-de-rived antibody with two binding sites to all isoforms of vascular endothelial growth factor. Intravitreal injection of bevacizumab is associated with possible ocular and systemic adverse effects. One particular concern with injection of a full-length IgG antibody is the potential for induction of an intraocular imniuno-logic response.
展开▼
